medigraphic.com
ISSN 1817-5996 (Electronic)

2014, Number 3

<< Back Next >>

Rev Cub de Reu 2014; 16 (3)

Phatogenycs´ mechanisms in the Systemic Sclerosis

Batista RES, Grass VA, Avilés CE, Pérez TL

Language: Spanish
References: 28
Page: 304-308
PDF size: 420.05 Kb.


ABSTRACT

In the systemic sclerosis the same as in rest of the illnesses that correspond to the group of the Connectivity’s their pathogeny it is not very established; in her it intervenes many factors like they are the genetic association, inheritance, environmental factors and inflammatory answer, their relationship with endogenous infections behaving from a special way to other inflammatory rheumatic illnesses. He/she is carried out a bibliographical revision of the inflammatory process that is developed in the systemic sclerosis as important part in the pathogeny of the illness, with the objective of to obtain bigger knowledge on the same one and to interpret in a better way the form in which the same one is developed to be able to use more effective therapeutic outlines in the treatment of the systemic sclerosis.


REFERENCES

  1. Chakravarty E. Pre-disease pregnancy complications and systemic sclerosis: pathogenic or pre-clinical? 2012;14(1):102.

  2. Milanetti F, Bucha J, Testori A, Burt RK. Autologous hematopoietic stem cell transplantation for systemic sclerosis. 2011;6(1):16-28.

  3. Mouthon L, Bérezné A, Bussone G, Noël LH, Villiger PM, Guillevin L. Scleroderma renal crisis: a rare but severe complication of systemic sclerosis. 2011;40(2):84-91.

  4. Dimitroulas T, Giannakoulas G, Karvounis H, Settas L, Kitas GD. Systemic sclerosis-related pulmonary hypertension: unique characteristics and future treatment targets. 2012;18(11):1457-64

  5. Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P, et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum. 2007;56(6):1985-93.

  6. Alarcón Segovia D. Tratado hispanoamericano de Reumatología, volumen 2. Bogotá: Ed. Nomos S.A; 2006. p. 887-909.

  7. Johnson SR, Brode SK, Mielniczuk LM, Granton JT. Dual therapy in IPAH and SSc-PAH. A qualitative systematic review. 2012;106(5):730-9

  8. García de la Peña Lefebvre P. Aspectos clínicos novedosos en la esclerodermia. Reumatología Clínica. 2008;4 Suppl 1:S45-9.

  9. Mouthon L, Rannou F, Bérezné A, Pagnoux C, Arène JP, Foïs E, Poiraudeau S. Development and validation of a scale for mouth handicap in systemic sclerosis: the Mouth Handicap In System Sclerosis scale (MHISS). Ann Rheum Dis. 2007;66(12):1651-5.

  10. Arnaud L, Huart A, Plaisier E, Francois H, Mougenot B, Tiev K, et al. ANCA-related crescentic glomerulonephritis in systemic sclerosis: revisiting the “normotensive scleroderma renal crisis” Clin Nephrol. 2007;68(3):165-70.

  11. Sfikakis PP, Papamichael C, Stamatelopoulos KS, Tousoulis D, Fragiadaki KG, Katsichti P, et al. Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis. Arthritis Rheum. 2007;56(6):1985-93.

  12. Barst RJ, Gibbs JSR, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Galiè N. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. Journal of the American College of Cardiology. 2009;54(1):78-84.

  13. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176(10):1026-34.

  14. Paone C, Chiarolanza I, Cuomo G, Ruocco L, Vettori S, Menegozzo M. Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol. 2007;25(4):613-6.

  15. Quillinan NP, Denton CP. Disease-modifying treatment in systemic sclerosis: current status. Current opinion in rheumatology. 2009;21(6):636-41.

  16. Fertig N, Domsic R, Rodríguez- Reyna T, Kuwuana M, Lucas M, Medsger T, Karol JR, Li-Bostwick F Anti–U11/U12 RNP Antibodies in Systemic Sclerosis: A New Serologic Marker Associated With Pulmonary Fibrosis. 2009;61(7):958-65.

  17. Leal Mursulí A, Rodríguez López E, Ramos Díaz N, Izquierdo Lara T, Adefna Pérez I. Esclerodermia como causa de sangramiento digestivo alto: A propósito de un caso. Rev Cubana cir [revista en Internet]. 2000 Abr [citado 25 jul 2014];39(1):82-4. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-74932000000100012&lng=es.

  18. Barriga Oropeza J, Murillo Sanchez C, Agreda Guerrero J. Esclerodermia o esclerosis sistémica. A propósito de un caso. Rev. bol. ped. [revista en Internet]. 2003 [citado 3 julio 2014];42(2):97-9. Disponible en: http://www.scielo.org.bo/scielo.php?pid=S102406752003000200004&script=sci_abstract

  19. Mustelier JV, Cabrera Rego JO, García Fernández R, López Mantecón AM. Miocardiopatía restrictiva y comunicación interauricular en un paciente con esclerodermia. Rev cubana med [revista en Internet]. 2010 Sep [citado 16 mayo 2014];49(3):275-81. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232010000300007&lng=es

  20. Romero-González A, Gil-Agramonte M, Ortiz-Labrada A, Tamayo-Rodríguez M, Álvarez Vladimir F, Suárez-Castillo JC, et al . Síndrome de Evans Fisher asociado con esclerodermia. Rev Cubana Hematol Inmunol Hemoter [revista en Internet]. 2014 Mar [citado 16 mayo 2014];30(1):81-8. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892014000100011&lng=es

  21. Leal Mursulí A, Rodríguez López E, Ramos Díaz N, Izquierdo Lara FT, Adefna Pérez RI. Esclerodermia como causa de sangramiento digestivo alto: A propósito de un caso. Rev Cubana cir [revista en Internet]. 2000 Abr [citado 16 mayo de 2014];39(1):82-4. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-74932000000100012&lng=es

  22. Kashif M, Qureshi A , Adil SN, Khurshid M. Successful use of Rituximab in Evans syndrome and refractory immune thrombocytopenic purpura. J Pak Med Assoc. 2010;60(1):64-5.

  23. Valentini G, Cuomo G, Abignano G, Petrillo A, Vettori S, Capasso A, Santoriello C. Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology. 2011;50(2):317-23.

  24. Allanore Y, Meune C, Kahan A. Systemic sclerosis and cardiac dysfunction: evolving concepts and diagnostic methodologies. Curr Opin Rheumatol. 2008;20(6):697-702.

  25. Leitão de MN, Azevedo Edda MT, Bernardini EF, Salles F, Heinzmann F, Marconde T, Mello, Rios Gomes BE. CysLT1 receptor inhibition in patients with Raynaud's phenomenon: capillaroscopic evidence of the role of leukotriene. Rev. Bras. Reumatol. 2012;52(1):30-2.

  26. Martins TC, Fernandes Adan RF. Autoimmune thyroid disease in patients with rheumatic diseases. Rev. Bras. Reumatol. 2012;52(3):423-30.

  27. Correia Leite C; Costa Maia A. Symptoms of disease and psychological adaptation in Brazilian scleroderma patients. Rev. Bras. Reumatol. 2013;53(5):405-11.

  28. Gerent Petry D, Len CA, Esteves MO, Ramos Ascensão MT. Nailfold capillaroscopy in children and adolescents with rheumatic diseases. Rev. Bras. Reumatol. 2012;52(5):727-32.




2020     |     www.medigraphic.com